PRINCETON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a specialty medical device/pharmaceutical company focusing on advanced wound care, today announced that eleven clinical case series regarding its flagship product, MEDIHONEY®, will be presented at the upcoming October 22-25 Clinical Symposium on Advances in Skin & Wound Care in San Antonio. These presentations include:
"Active Leptospermum Honey and Negative Pressure Wound Therapy for Non-Healing Post-Surgical Wounds"
Edna Acuna, MD
Medical Director, Wound & Hyperbaric Clinic, Methodist Medical Center, Dallas, TX
"Honey under Negative Pressure Wound Therapy: A New Approach to Removing Devitalized Tissue"
Paul A. Ligouri, MD, Kim L. Peters, RN, CWS, Jolene Bowars, RN, and Sandra Senno, MD
Haverhill Rehabilitation Hospital, Haverhill, MA
"Use of Honey Dressings for Infected Left Ventricular Assist Device Wounds"
Genevieve O'Shea, BN, RN, CCRN and Kathleen Lockard, BSN, RN, MBA
Artificial Heart Program, University of Pittsburgh, Pittsburgh, PA
"Evidence Based Practice for Pediatric Wound Care: Utilizing Active Leptospermum Honey as a Primary Dressing for Chronic Wounds"
Charlene Deo, RN, CWOCN
Lucile Packard Childrens Hospital at Stanford, Palo Alto, CA
"Active Leptospermum Honey for Pediatric Wound Care: Moving Evidence into Practice"
Roxana Reyna, RNC, WCC
Driscoll Children's Hospital, Corpus Christi, TX
"The Clinical Benefits of Active Leptospermum Honey: Oncologic Wounds"
Debbie Segovia, RN, MSN, CWOCN
Cancer Treatment Centers of America, Tulsa, OK
"Active Leptospermum Honey for Frostbite, PIN Sites, and Skin Tears"
Elizabeth Bodie Gross, RN, APN, WCC
Quality Health Unlimited, Chicago, IL
"Utilizing Active Leptospermum Honey Dressings in the Treatment of Cutaneous Small Vessel Vasculitis"
M Allison Hendrickson, DO
Wound Management Program Baylor All Saints, Fort Worth, TX
"Active Leptospermum Honey for the Treatment of Recalcitrant Lower Extremity Wounds"
Nancy Chaiken, ANP-C, CWOCN
Swedish Covenant Hospital, Chicago, IL
"Use of Active Leptospermum Honey Dressings in the Home Care Setting"
Timothy Larsen, RN, BSN, CWOCN, Sue Reif, RN, BSN, CWOCN, and Kathy Tavernelli, RN-BC, BSN, CWOCN
Cleveland Clinic Home Care, Cleveland, OH
"Evidence Based Practice: Active Leptospermum Honey Dressings for Tertiary Care"
Diane Maggio, RN-BSN, CRRN, CWON
Wound, Ostomy, Continence Nurse, AtlantiCare Regional Medical Center, Atlantic City, NJ
With regard to the presentations at the Clinical Symposium, Edward J. Quilty, Chairman and Chief Executive Officer of Derma Sciences, stated, "We are very excited to see the number of case series submitted and accepted for presentation at this prestigious wound healing conference. The breadth of evidence being generated around the use of MEDIHONEY - in multiple wound types, in multiple care settings, and in multiple patient populations - is clearly being reflected in our growing sales numbers achieved each quarter. To be playing such a crucial role in so many patients' lives is very rewarding. As an example, one presentation by clinicians from the Artificial Heart Program at the University of Pittsburgh, utilizing the benefits of MEDIHONEY for left ventricular assist device driveline sites, shows the tremendous benefit to outcomes in quite a dire clinical situation."
"Additionally," Quilty continued, "we are very enthusiastic about the commercial potential in the utilization of MEDIHONEY along with negative pressure wound therapy (NPWT) devices. This advanced type of device for wound healing has been the largest driver of growth in the advanced wound care field, achieving sales in the US of over $1.2 billion in 2008, with several thousand applications being done daily. Evidence around improved outcomes from this type of application opens up a whole new venue for us, and will help to solidify MEDIHONEY's place as a primary adjunct to NPWT."
Quilty, commenting on the use of MEDIHONEY in the pediatric and oncologic settings, said, "These are very difficult patient sets due to toxicity issues involving currently available products. We are delighted that clinicians are increasingly aware of MEDIHONEY, and that the product line can deliver consistent healing benefits without toxicity concerns. Oncologic wounds are specialty wounds with unique causes and issues. MEDIHONEY dressings are proving to be very beneficial for these wound types."
Quilty concluded, "Our products continue to make a meaningful difference in the lives of patients with chronic and hard-to-heal wounds. The evidence supporting our new technologies is growing, as is our reputation in the field of advanced wound care."
The Clinical Symposium on Advances in Skin & Wound care is an annual conference, held this year October 22-25, 2009, in San Antonio. The goal of the 24th annual event is to meet the continuing-education needs of multidisciplinary skin and wound care practitioners, from novice to expert, by providing a forum for educational sessions and interactive workshops that offer comprehensive wound management strategies. Over 1,100 multidisciplinary practitioners, including nurses, physicians, podiatrists, physical therapists, dietitians and others who manage skin and wound care patients across the continuum of health care, are expected to attend. For more information on the symposium, please go to www.symposiumonwoundcare.com.
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY®, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.
For more news and information on Derma Sciences, Inc., please visit www.IRGnews.com/coi/DSCI where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.
Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.
Contact: Derma Sciences, Inc. Edward J. Quilty Chairman and CEO email@example.com (609) 514- 4744 Contact: The Investor Relations Group 212-825-3210 Investor Relations: Jason Strominger Or Media Relations: Susan Morgenbesser
SOURCE Derma Sciences, Inc.
|SOURCE Derma Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved